<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00169156</url>
  </required_header>
  <id_info>
    <org_study_id>RAIL</org_study_id>
    <secondary_id>2005-002602-37</secondary_id>
    <nct_id>NCT00169156</nct_id>
  </id_info>
  <brief_title>A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma</brief_title>
  <official_title>Study of the Efficacy and the Safety of First Line Treatment With CHOP Plus Rituximab (R-CHOP) in Patients Aged 60 to 80 Years With Previously Untreated T-cell Angioimmunoblastic Lymphoma (AIL).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lymphoma Study Association</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Lymphoma Study Association</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and the safety of a front-line treatment combining CHOP regimen and
      rituximab in patients aged 60 to 80 years with previously untreated AIL.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicentric, open-label, non-randomized clinical study, evaluating the efficacy
      and the safety of a front-line treatment combining CHOP regimen and rituximab in patients
      aged 60 to 80 years with previously untreated AIL.

      It is anticipated that 25 subjects will be enrolled over 2 years (from 2005 / 2007).Analysis
      performed every 5 patients (based on triangular test).

      The duration of the treatment period is approximately 25 weeks and patients are followed
      until Death.

      The total Duration of the study is expected to be 2.5 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2005</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>8 months (4 cycles of treatment + 4 cycles of consolidation)</time_frame>
    <description>[Complete response (CR), Complete response unconfirmed (CRu)] after the end of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event-free survival (EFS) relapse for complete responders, disease progression, early discontinuation of treatment for toxicity or modification of treatment.</measure>
    <time_frame>2 years</time_frame>
    <description>Events being death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression (TTF)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival (DFS).</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of SAE</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Untreated T-cell Angioimmunoblastic Lymphoma</condition>
  <arm_group>
    <arm_group_label>Rituximab + CHOP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rituximab + CHOP regimen Prednisone - Doxorubicine - Cyclophosphamide - Vincristine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>375 mg/m2 D1</description>
    <arm_group_label>Rituximab + CHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>40 mg/m2 D1 to D5</description>
    <arm_group_label>Rituximab + CHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicine</intervention_name>
    <description>50 mg/m2 D1</description>
    <arm_group_label>Rituximab + CHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>750 mg/m2 D1</description>
    <arm_group_label>Rituximab + CHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>1,4 mg/m2 D1</description>
    <arm_group_label>Rituximab + CHOP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histologically proven T-cell angioimmunoblastic lymphoma (AIL) on lymph
             node biopsy.

          -  Aged from 60 to 80 years.

          -  Patient not previously treated (except corticosteroids providing they have been
             initiated less than 10 days before inclusion).

          -  ECOG performance status 0 to 2.

          -  With a minimum of life expectancy &gt; 3 months.

          -  Negative HIV, HBV and HCV serological tests &lt; 4 weeks (except after vaccination).

          -  Having previously signed a written informed consent.

        Exclusion Criteria:

          -  Any other histological type of T-cell lymphoma.

          -  Central nervous system or meningeal involvement by lymphoma.

          -  Contra-indication to any drug included in the R-CHOP regimen.

          -  Concurrent severe disease (according to the investigator's decision).

          -  Active bacterial, viral or fungal infection.

          -  Poor renal function (serum creatinine level &gt; 150 µmol/L) or impaired liver function
             tests (total bilirubin level &gt; 30 µmol/L, transaminases &gt; 2.5 upper normal limits)
             unless they are related to the lymphoma.

          -  Poor bone marrow reserve as defined by neutrophils &lt; 1.5 x 109/L or platelets &lt; 100 x
             109/L, unless related to bone marrow infiltration.

          -  Any history of cancer during the last 5 years, with the exception of non basal cell
             carcinoma of the skin or in situ carcinoma of the cervix.

          -  Treatment with any investigational drug within 30 days before planned first cycle of
             chemotherapy and during the study.

          -  Patient under tutelage.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Corinne Haioun, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hôpital Henri Mondor, Créteil, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bertrand Joly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>C.H. Sud Francilien, Corbeil-Essonnes, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hématologie - Centre Hospitalier Lyon-Sud</name>
      <address>
        <city>Pierre-Bénite cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.gela.org</url>
    <description>Official site of the Groupe d'Etude des Lymphomes de l'Adulte (In french)</description>
  </link>
  <reference>
    <citation>Attygalle A, Al-Jehani R, Diss TC, Munson P, Liu H, Du MQ, Isaacson PG, Dogan A. Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10. Blood. 2002 Jan 15;99(2):627-33.</citation>
    <PMID>11781247</PMID>
  </reference>
  <reference>
    <citation>Lome-Maldonado C, Canioni D, Hermine O, Delabesse E, Damotte D, Raffoux E, Gaulard P, Macintyre E, Brousse N; French Groupe d'Etude des Lymphomes de l'Adulte (GELA). Angio-immunoblastic T cell lymphoma (AILD-TL) rich in large B cells and associated with Epstein-Barr virus infection. A different subtype of AILD-TL? Leukemia. 2002 Oct;16(10):2134-41.</citation>
    <PMID>12357368</PMID>
  </reference>
  <reference>
    <citation>Zettl A, Lee SS, Rüdiger T, Starostik P, Marino M, Kirchner T, Ott M, Müller-Hermelink HK, Ott G. Epstein-Barr virus-associated B-cell lymphoproliferative disorders in angloimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified. Am J Clin Pathol. 2002 Mar;117(3):368-79.</citation>
    <PMID>11888076</PMID>
  </reference>
  <reference>
    <citation>Gisselbrecht C, Gaulard P, Lepage E, Coiffier B, Brière J, Haioun C, Cazals-Hatem D, Bosly A, Xerri L, Tilly H, Berger F, Bouhabdallah R, Diebold J. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood. 1998 Jul 1;92(1):76-82.</citation>
    <PMID>9639502</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>March 9, 2017</last_update_submitted>
  <last_update_submitted_qc>March 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>T-cell angioimmunoblastic lymphoma</keyword>
  <keyword>Rituximab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

